Amgen Settles False Claims Act Allegations
Amgen has agreed to pay $762 million to resolve criminal liability and false claims act allegations.
Amgen has pleaded guilty to a single misdemeanor count for illegally introducing a misbranded drug into interstate commerce and has agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.
According to a Justice Department press release, the government alleged that Amgen promoted their erythropoiesis-stimulating drug, Aranasep, for off-label use. Aranasep was approved by FDA at calibrated doses for particular patient populations suffering from anemia. In order to increase sales of Aranesp, the government said that Amgen illegally sold the drug with the intention that it be used at off-label doses that FDA had specifically considered and rejected, and for an off-label treatment that FDA had never approved. Under the terms of the criminal plea agreement, Amgen will pay a criminal fine of $136 million and criminal forfeiture in the amount of $14 million.
As part of the civil settlement, Amgen has agreed to pay $612 million to resolve allegations that it caused false claims to be submitted to Medicare, Medicaid, and other government insurance programs. The federal civil settlement agreement encompasses allegations that Amgen:
- Promoted Aranesp and two other drugs, Enbrel and Neulasta, for off-label uses and doses that were not approved by FDA and not properly reimbursable by federal insurance programs
- Offered illegal kickbacks to a wide range of entities in an effort to influence health care providers to select its products for use
- Engaged in false price reporting practices involving several of its drugs.
As part of the global settlement, Amgen has also agreed to enter into a corporate integrity agreement with the Department of Health and Human Services that will govern its conduct, and ensure careful oversight of its branding and marketing practices.
"The government raised important concerns in the criminal prosecution. Amgen acknowledges that mistakes were made, and we did not live up to our standards," said Cynthia M. Patton, senior vice president and chief compliance officer at Amgen in a company news release. "This Corporate Integrity Agreement is aligned with the significant changes and enhancements we have made to our compliance program and demonstrates our commitment to fostering a culture of compliance at Amgen."
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance (May 2025)
May 16th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.
